The Chase Group Executive Search Logo
“Committed to Excellence in Life Sciences Executive Search”

Through Partnership with The Chase Group, Aeglea BioTherapeutics Continues Building Rare Disease Clinical Development Leadership Team

August 12, 2019
The Chase Group is honored to continue our partnership with Aeglea BioTherapeutics as we work to build their Rare Disease Clinical Development Leadership team. As a clinical-stage biotechnology company, Aeglea is engineering next-generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical needs. To support its expanding portfolio of rare disease programs, Aeglea has retained The Chase Group to recruit a Global Medical Lead, Early Pipeline Programs. This position provides a unique opportunity for an individual to join an organization with a lead asset, Pegzilarginase, that has progressed into a pivotal study for Arginase 1 deficiency, and two pipeline programs in IND-enabling studies for homocystinuria and cystinuria, that will be advancing into the clinic in 2020. For more information please contact Moira Newbanks moira@chasegroup.com

Chase Group

Share This News Post

© Copyright 1993-2019 The Chase Group; All Rights Reserved.